Pathology: la/mBC - HER2 positive - 1st Line (L1); la/mBC - HR-positive - 1st line (L1);
la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HR-positive - 1st line (L1) | ||
SYSUCC-002, 2022 | SYSUCC-002, 2022 | ||
trastuzumab plus endocrine therapy | 2 | T1 | T1 |
trastuzumab plus chemotherapy | 0 | T0 | T0 |